Advisors Preferred’s Belite Bio BLTE Stock Holding History

Advisors Preferred’s Portfolio BLTE Stock Details BLTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-798	Closed	-$51.7K	–	252
2024 Q4	$51.7K	Buy	+798	New	+$52.6K	0.01%	156

Other funds holding BLTE

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

VIA

Virtus Investment Advisers Hartford, Connecticut $363M AUM 34.89% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Advisors Preferred's BLTE Position: Q1 2025 in Review

Advisors Preferred sold out of Belite Bio (BLTE) in Q1 2025, closing a stake of 798 shares — an estimated $51.7K sold.

Advisors Preferred first reported a position in BLTE in Q4 2024 and held it in 1 quarter. The position peaked at $51.7K in Q4 2024. 18 funds tracked by Wall St. Rank hold BLTE as of Q1 2025.

Advisors Preferred reported no remaining Belite Bio position as of Q1 2025 after selling out during the quarter.
Advisors Preferred sold 798 Belite Bio shares in Q1 2025, an estimated $51.7K.
Advisors Preferred first reported a position in Belite Bio in Q4 2024 and held it in 1 quarter.
Advisors Preferred's Belite Bio position peaked at $51.7K in Q4 2024.
18 funds tracked by Wall St. Rank held Belite Bio as of Q1 2025.

Based on Advisors Preferred's 13F filing for Q1 2025, filed 6 May 2025.